Author: garysagiv0045

  • What’s new this week in US MedTech, 5 to 12 November 2026

    What’s new this week in US MedTech, 5 to 12 November 2026

    What's new this week in US MedTech, 5 to 12 November 2026

    5 to 12 November 2026

    This is the first of a new Thursday series on US MedTech. It was a week in which the FDA both opened doors and closed one: two De Novo authorizations and a carotid PMA, a 510(k) in wound care, a CMS reversal that will pay for a new breast imaging exam, two US financings, and a discussion paper on surgical robots that can work on their own or from a distance.

    1. Contego Medical wins FDA PMA for Neuroguard IEP Direct, a new TCAR-IEP approach

    On 10 November Raleigh based Contego Medical announced FDA premarket approval of the Neuroguard IEP Direct System and 510(k) clearance of the Neuroguard IEP Embolic Protection System. Used together, they provide dual neuroprotection through flow reversal and an integrated embolic protection filter via direct transcarotid access, which the company describes as a new approach category, TCAR-IEP, for carotid revascularization. In the PERFORMANCE III pivotal study, the 30-day stroke rate was 0% in the intention-to-treat population, with no myocardial infarctions, cranial nerve injuries, neurological deaths or stent thromboses. The primary endpoint, the 30-day rate of major adverse events, was 0.69% in the intention-to-treat population and 0% in the per-protocol population. The earlier Neuroguard IEP 3-in-1 system received FDA PMA approval in October 2024 for transfemoral and transradial carotid stenting and is commercially distributed by Medtronic. It matters because a PMA built on a 0% 30-day stroke rate gives physicians a transcarotid option that adds a filter to flow reversal.

    Source: PRWeb (Contego Medical)

    2. Virtuoso Surgical receives FDA De Novo authorization for its endoscopic robot

    On 10 November Nashville based Virtuoso Surgical announced that the FDA granted De Novo authorization for the Virtuoso Endoscopy System on 30 October 2026. It is the first device in a new FDA classification, electromechanical surgical systems for endoluminal surgical procedures. The system places two needle-sized robotic arms at the tip of a rigid endoscope, giving urologists two-handed dexterity for en bloc resection of bladder lesions through the urethra, so pathologists can receive a tissue sample that includes detrusor muscle. The system received FDA Breakthrough Device designation in September 2025, and Virtuoso plans a focused US launch at leading urology centers in 2027. It matters because a new device class has been created for a small robotic system designed to take a better diagnostic specimen, not only to remove a tumor.

    Source: Virtuoso Surgical

    3. Theraclion’s Sonovein wins FDA De Novo authorization for non-invasive vein treatment

    On 5 November French company Theraclion announced that the FDA granted De Novo marketing authorization for Sonovein on 4 November 2026. In the United States, Sonovein is intended for the coagulation of blood vessels in patients with superficial vein reflux in Great Saphenous Vein segments, using high intensity focused ultrasound from outside the body, without an incision or an intravascular catheter. The company says it is the first non-invasive HIFU platform to receive US marketing authorization for this use. Authorization was supported by the VEINRESET pivotal study of 70 patients at four US and European centers (NCT05926830), which met its primary endpoint with a 96.8% GSV occlusion rate at 12 months. No serious or unanticipated adverse events were reported, and only one mild adverse event was observed. A dedicated Category III CPT code has been active since 1 October 2026, which Theraclion describes as an initial step toward coverage and payment. The company has established a US subsidiary, Sonovein Inc., and says it is ready to begin commercial launch. It matters because a European company has opened the US vein market with a truly non-invasive approach, while payment pathways are still being built.

    Source: Theraclion

    4. FDA declines to approve Novocure’s Optune Mya for brain metastases from lung cancer

    On 9 November Novocure (Nasdaq: NVCR) said it had received a Not Approvable Letter from the FDA in response to its PMA application for Optune Mya, for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The FDA determined that uncertainty around the degree of clinical benefit prevented approval. The agency did not raise concerns related to the safety profile. Novocure plans to meet with the FDA to determine whether there are options that would support approval without additional clinical studies, and cautions that there can be no assurance those discussions will lead to an approval. The company’s US headquarters is in Portsmouth, New Hampshire. It matters because even a well known oncology device company can be turned back when the FDA is not convinced of the clinical benefit.

    Source: Novocure

    5. Luminoah raises $25M Series B, and EnVision Endoscopy closes an $11.5M Series A

    On 10 November Charlottesville based Luminoah announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The round includes $20 million in new equity and $5 million in previously issued convertible notes that converted as part of the financing. The money will expand distribution of Luminoah Flow, the company’s FDA-cleared enteral feeding system (cleared in April 2026), increase manufacturing capacity, and continue development of Luminoah Intelligence, its clinician-facing data platform. The same day, Waltham based EnVision Endoscopy announced an oversubscribed $11.5 million Series A led by Puma Venture Capital, with participation from UTEC (University of Tokyo Edge Capital), existing investor Olympus Corporation of the Americas, and MassVentures. EnVision received FDA clearance for its SimpleStitch Suturing System in 2025, began a limited US market release in 2026, and has now completed its first 50 patient procedures. It matters because US investors are still funding companies that have already cleared the FDA and are now trying to get the technology into everyday use.

    Source: Luminoah and PR Newswire (EnVision Endoscopy)

    6. CMS reverses course and will pay for outpatient QTscan breast imaging from 2027

    On 9 November QT Imaging Holdings (Nasdaq: QTI) announced that CMS has established separately payable Medicare hospital outpatient payment for medically necessary, physician-ordered diagnostic QTscan examinations, effective 1 January 2027. The decision reverses CMS’s earlier proposal to classify QTscan examinations as nonpayable. Under the final 2027 Medicare Hospital Outpatient Prospective Payment System rule, CMS assigned QTscan’s dedicated CPT code 1079T to Ambulatory Payment Classification 5522, with status indicator S. The CPT code itself became effective on 1 October 2026. Routine screening of asymptomatic patients is not covered under current Medicare rules, and payment remains subject to medical necessity and documentation requirements. It matters because a clearance without payment often sits on the shelf, and this reversal gives hospitals a real reason to offer the exam.

    Source: QT Imaging

    7. Bechtel Medical receives 510(k) clearance for Wound VOX, combining negative pressure and topical oxygen

    On 10 November Phoenixville, Pennsylvania based Bechtel Medical announced 510(k) clearance from the FDA for Wound VOX. The company describes it as the first 510(k)-cleared system to combine negative pressure wound therapy and topical oxygen therapy on one platform, with three modes: continuous NPWT, intermittent NPWT, and intermittent NPWT with adjunctive topical oxygen. The company notes that topical oxygen therapy has faced reimbursement challenges, and plans a limited commercial release in December 2026. It matters because combining two therapies in one device may make treatment simpler for clinicians, but payment will still decide how widely it is used.

    Source: PR Newswire (Bechtel Medical)

    8. FDA asks for views on autonomous and remotely operated surgical robots

    On 6 November the FDA’s Center for Devices and Radiological Health released a discussion paper on evaluating benefit and risk in robotic medical devices with autonomous or remote teleoperation capabilities, including devices for surgery and for positioning or controlling instruments or imaging tools. The paper is for discussion only and does not represent draft or final guidance, and is not intended to propose or implement policy changes. Comments are requested under docket FDA-2026-N-13135 by 5 January 2027. It matters because the agency is inviting a conversation on telesurgery and autonomy before it writes the rules, and companies working in this area should take the chance to speak up.

    Source: FDA and American Hospital Association

    Gary’s take

    This week I kept coming back to a simple thought: getting through the FDA is only half the job. Contego, Virtuoso and Theraclion all earned important authorizations, and that is genuinely good news for patients. But a device that is cleared and not paid for often waits a long time before it reaches the people who need it. The QTscan story is a reminder of that, because CMS first proposed not to pay and then changed its mind, which is what will actually help hospitals offer the exam from January 2027. Theraclion already has a Category III CPT code, and Bechtel Medical itself notes that topical oxygen still faces reimbursement challenges. The Novocure decision shows the other side, that the FDA will still say no when it is not convinced of the clinical benefit, even for a company that already has products on the market. I would love to hear from people who have lived through this.

    Once you have the FDA letter in your hand, what has been the harder part, the regulatory path or getting paid? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.


    Sources note: all items were found through a public web scan of about 5 to 12 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. NIH SBIR awards announced in this window by Linshom Medical (a $3.5 million Phase 2B grant on 5 November) and Highland Instruments (a Phase IIB award announced on 9 November, with about $1.5 million in current year funding and about $1.4 million in recommended future support, subject to availability of funds and satisfactory progress) were covered in the 3 to 10 November funding and deals edition. Late breaking trial results from TCT were presented on 2 and 3 November, just before this window. No US medtech IPO pricing in this window was confirmed.

    Download the full roundup as a PDF

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

  • What’s new this week in European MedTech, 4 to 11 November 2026

    What’s new this week in European MedTech, 4 to 11 November 2026

    4 to 11 November 2026

    This is the first of a new Wednesday series on European MedTech. It was a week of steady, practical news rather than mega rounds: home dialysis and home stroke rehabilitation raised fresh money, sepsis and urology companies funded their next push across Europe, two European groups bought their way into new countries and new capabilities, two Korean companies cleared the MDR to enter Europe, and the European Parliament moved one step further on the MDR and IVDR revision.

    1. Nextkidney raises more than €20M Series C for its portable home dialysis device

    On 10 November Dutch medtech company Nextkidney said it had raised more than €20 million in a Series C round to complete development of the Neokidney, a portable hemodialysis device, and prepare it for market, with 3O Health among the investors and Dutch health insurers CZ, Menzis and Zilveren Kruis also involved. It is running a crowdfunding campaign through Invesdor for a further €3 million. The company reports 500 completed treatments across four medical centres in the Netherlands, Belgium and France, and this month starts a study in which patients perform 500 treatments independently outside the hospital. Subject to CE marking and FDA approval, it plans a first clinical launch at the end of 2027 and European home use in Q1 2028. It matters because European payers are putting their own money behind moving dialysis out of the hospital.

    Source: Dealroom News

    2. Bioliberty raises a €2.95M Series A extension to take stroke rehabilitation home

    On 6 November Edinburgh and Boston based Bioliberty announced a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million). New backers are TGH Ventures (the investment arm of Tampa General Hospital), Ballad Ventures, Belfast based Whiterock and 25m Health. The company makes soft robotic upper limb rehabilitation technology, mainly for stroke survivors, and will use the money to extend it into the home, connect rehabilitation data across care settings and add AI decision support. It matters because rehabilitation after stroke is slowly moving from the clinic to the living room.

    Source: EU-Startups

    3. Efferon raises €4.3M to grow its sepsis blood purification devices

    On 10 November Efferon, which develops hemoadsorption devices that remove endotoxins and excess inflammatory mediators from the blood, said it had raised €4.3 million from existing private investors in the DACH region. Its devices are approved and used across Europe, are distributed in 46 countries, and have been used in more than 30,000 treatments. The money supports expansion of Efferon LPS and Efferon NEO in Europe, India and Latin America, its network of 21 distributors, regulatory work and clinical evidence. The company reported revenue above €1.1 million in 2025 and expects intensive care revenue of about €5 million in 2027. It matters because a small European critical care company is funding growth from loyal investors while it prepares for a full Series A.

    Source: Tech.eu

    4. Active Medical Xcellence closes a seven figure round for urological endoscopy

    On 9 November Jena based Active Medical Xcellence (AMX), a spinout of Active Fiber Systems, announced a seven figure growth round led by bm|t through the Thuringia Growth Equity Fund II, with MBG Thüringen, Sparkasse Jena Saale Holzland and a business angel joining. The money will expand sales and international reach for its MDR approved activeCut morcellator, used to treat benign prostatic obstruction, and develop its pipeline. It matters because regional public and savings bank capital in Germany is still backing small device makers that already carry an MDR certificate.

    Source: bm|t

    5. Two European deals: Rosti buys Alvi, and Eqwal buys the Preisler Group

    On 9 November Malmö based Rosti Group announced it has acquired Alvi Group, adding five sites in Leksvik (Norway), Tyresö (Sweden), Wrocław (Poland) and Suzhou (China) and about 400 colleagues. Alvi adds EUR 50 million to Rosti’s EUR 400 million in revenue, financial terms were not disclosed, and the acquisition took place on 2 November. On 6 November Eqwal Group announced the acquisition of the Preisler Group in Langen, Hesse, with 82 employees across technical orthopaedics, neurological therapy and assistive device distribution. It matters because European consolidation is happening quietly in the less glamorous parts of the chain, in contract manufacturing and in orthopaedic and rehabilitation care.

    Source: PR Newswire (Rosti Group) and Eqwal Group

    6. Two Korean companies win CE marking under the MDR

    On 10 November Seoul based RF Medical announced CE marking under the EU MDR for its Mi-BLATOR microwave ablation system, covering both the generator and the antennas, following the MDR CE marking of its THYBLATE-V2 thyroid RFA electrode in September 2026. The same day Beamworks said its breast ultrasound AI software CadAI-B Dx received CE marking under the EU MDR as a Class IIb device, after its earlier FDA 510(k) clearance. It matters because companies from outside Europe are still investing the time and money to get through MDR, and Europe remains a market they want.

    Source: PR Newswire (RF Medical) and Maeil Business (Beamworks)

    7. MDR and IVDR revision: Parliament’s IMCO committee adopts its opinion

    On 10 November the European Parliament’s Internal Market and Consumer Protection committee (IMCO) adopted its opinion on the MDR and IVDR revision, with all four negotiated compromise amendments winning a majority. The Budgets committee opinion is dated 5 November. The lead Public Health committee (SANT), with Oliver Schenk as rapporteur, has still not voted, the Legislative Observatory lists 14 December 2026 as an indicative plenary date, and health ministers meet on 8 December. Until a final text is adopted, which industry sources expect around Q2 to Q3 2027, the current MDR and IVDR apply in full and the transition deadlines of 31 December 2027, 2028 and 2029 are unchanged. It matters because every company planning a European launch is still working under today’s rules.

    Source: Pharma Deutschland and European Parliament Legislative Observatory

    8. MedTech Europe calls for repeal of the SCIP database

    On 4 November MedTech Europe and other associations published a joint statement asking EU policymakers to confirm the repeal of the SCIP database for substances of concern, as proposed by the European Commission under the Environmental Omnibus. They argue that after five years it duplicates information already required under REACH Article 33(1) and creates costly reporting, especially for SMEs and makers of complex products. It matters because the push to cut duplicated EU reporting now reaches well beyond the MDR itself.

    Source: MedTech Europe

    Gary’s take

    I want to put a gentle question mark over the MDR this week, because I am honestly not sure of the answer myself. My feeling is that the MDR has gone too far, and that a great deal of what it produces is Brussels bureaucracy rather than safer patients. Many good new products simply never reach the European market, and companies quietly launch in the US or Asia first, or not in Europe at all. Is that good or bad? Some will say it protects patients, and I respect that view. But when I look at hospitals around Europe, I believe European healthcare is paying a price, and most people are not aware of it. The technology world knows, but I am not sure doctors, healthcare reformers, or even the people who run the MDR see what is missing from their own clinics. This week’s news shows both sides, with companies like AMX, RF Medical and Beamworks getting through, and Brussels still debating how to simplify. I would love to hear what you see from where you sit.

    Has the MDR made European patients safer, or has it mainly kept good technology away from them? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of about 4 to 11 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. No new EIC Accelerator or Horizon results for medtech were published in this window, and no new MDR notified body designation was found.

    Download the full roundup as a PDF

  • How to Select the Right International Market for Your Medical Device

    How to Select the Right International Market for Your Medical Device

    When founders show me their international plans, there is often a map with a lot of flags on it. I understand the instinct, because the need for good medical technology is everywhere and every country looks like an opportunity from a distance. But international market entry for a medical device is expensive in time, money and attention, and a small company can usually do only a few countries properly at once. Choosing which ones, and in what order, is one of the most important commercial decisions a young company makes.

    I have worked on products that reached customers in 117 countries, and I have learned that the right first market is rarely the biggest one or the most exciting one. It is the one where the clearance you hold, the money that pays for care and the people who will actually sell for you all line up. This is where a phrase I learned nearly 25 years ago from a consultant makes the most sense: make friends before you need them. It is also where Synergen can help, because we already have the friends!

    Start with the clearance you already hold

    The first filter is regulatory, and it is the one founders most often leave until too late. Every market has its own registration process, and some of them take far longer than anyone expects. If your device already has an FDA clearance or a CE mark, it makes sense to look first at the markets that accept or rely on that clearance, because sales can begin sooner while longer registrations run in the background. Remember, though, that outside the USA an FDA clearance is only the start of the process, and today it is becoming much harder to enter many countries, because local registration is more demanding than ever.

    I also encourage companies to build one master regulatory file from the beginning. When the core documentation is kept in one place and kept current, each new country becomes a gap analysis rather than a completely new project, and that changes the economics of entering the third, fifth and tenth market. Many years ago, on behalf of a company I represented at the time, I published a notice on LinkedIn looking for a Chinese regulatory expert with experience of submissions to the Chinese authority, because it was clear that some markets simply cannot be approached without real local regulatory knowledge. That is worth knowing before a country goes on the list, not after.

    Who pays for care in your target market

    The second filter is money, and specifically whose money. A device that is reimbursed in one country may have to be paid for out of pocket in another, and that changes everything about price, positioning and the speed of adoption. On a trip through Southeast Asia in 2024 for a Synergen client, I noted that there is very little private pay in Thailand, and in Vietnam I wrote quite bluntly in my report that the regulatory process would be very difficult and long and that price sensitivity was high. Neither observation made those countries wrong for the product, but both meant that the business model had to be designed for them rather than copied from somewhere else. As for Vietnam, I must add in retrospect that, thanks to an excellent distributor we brought on board, we were able to overcome many of those barriers, and it has become one of the best successes for that company.

    At the end of that report I wrote a sentence that I now use with almost every client: we need to ask ourselves if these countries are real, viable opportunities. I asked whether there was a pricing model and a minimum volume that could make the opportunity viable for all parties. I asked which medical devices had already succeeded there, and in what volumes. And I asked how long it would realistically take to get through regulation and then win over doctors and patients. None of those questions had easy answers, but asking them before signing anything saved a great deal of disappointment later.

    International market entry depends on real demand

    Need and demand are different things, and confusing them is one of the most common mistakes I see. A country can have an enormous medical need and still have very little demand for your particular device, because clinicians do not know the technology, cannot be trained on it, or cannot fit it into the way they work.

    An example from my own experience in rehabilitation illustrates the point. In 2024 we ran a small telephone survey of 20 physical therapists, most of them in Bangkok, and only 15 percent of them had ever used robotic rehabilitation products. When we asked why, they talked about cost, lack of training, thin evidence and the fact that the systems could not easily be moved. The need for rehabilitation was obvious, but the survey told us that a company entering that market would have to invest in education and training before it could expect orders. That is the kind of finding that should shape a market plan, and it cost very little to obtain.

    Can you be there in person?

    The third filter is presence, and it is the one that small companies most often overestimate. Every market you enter will need visits, training and attention for years, and a distributor in a country you never visit will eventually stop prioritizing you. Before a country goes on the list, it is worth asking honestly who in your company will travel there, how often, and who will answer the distributor’s questions when the time difference means your office is asleep. If the answer is the same two people who are already covering five other markets, the new country will suffer, and so will the existing ones. My personal rule for success is a minimum of two visits a year, and even better, a visit every quarter if possible, even if it is only for one day!

    Preparation also differs from country to country. Some markets expect a short and precise presentation, others want to see the device working on real patients before they believe anything, and some want months of relationship building before a serious commercial conversation even begins. None of these is better than the others, but each one asks for a different kind of preparation and a different budget of time. If you cannot prepare properly for the way a market makes decisions, it is probably not your next market yet.

    Using the help that already exists

    Founders often do not realize how much support is available for this decision. Export institutes, economic missions in embassies, trade fairs and industry associations all hold knowledge about markets that a small company could never gather alone, and most of them are glad to share it with a company that arrives with good questions. A few phone calls before the ranking is finished can save months of travel later.

    The most useful thing you can do is to turn the map into a short, honest ranking. Put each candidate market through the same questions about clearance, payment, demand and presence, choose two or three that pass, and do those well before adding more. A company that wins two markets properly is in a far stronger position, with investors and with the next distributor, than one with ten signed agreements and no reorders.

    If you are trying to decide where your device should go next, I would be glad to look at the options with you. Write to me at gary@synergenmedtech.com and tell me about your commercialization or international business development challenges. In the next article, I explain why the USA and the EU are not always the right place to start.

    All names of people and partners have been removed for privacy reasons.

  • What’s new this week in MedTech funding and deals, 3 to 10 November 2026

    What’s new this week in MedTech funding and deals, 3 to 10 November 2026

    3 to 10 November 2026

    This is the first of a new Tuesday series on MedTech funding and deals. It was a heavy week for capital: Boston Scientific and Blackstone agreed a large co-funding package for a heart pump, GE HealthCare led a major Series B for AI robotic imaging in the cath lab, Chinese investors put close to RMB 1 billion into brain computer interfaces, Rockwell Medical agreed to buy a global hemodialysis business, and two listed Chinese device groups took a large strategic stake that may lead to a merger. NIH grants also backed smaller device teams in respiratory monitoring and Parkinson’s neuromodulation.

    1. Boston Scientific and Blackstone Life Sciences agree up to $455M to co-fund the Vitalyst heart pump

    On 2 November, just as this week opened, Blackstone Life Sciences announced a collaboration under which it will provide up to $455 million to co-fund development of Boston Scientific’s VITALYST Temporary Percutaneous Transvalvular Circulatory Support System for acute myocardial infarction cardiogenic shock. It is the first time the two have co-funded a Boston Scientific product. Blackstone may receive regulatory and commercial milestone payments of up to about 2.5 times the capital it provides, plus royalties on net sales, and Boston Scientific has said it expects to start those payments in 2030. It matters because a capital heavy late stage device programme is being financed by sharing cost with a deep pocketed partner, rather than by a conventional equity round.

    Source: Blackstone and MedTech Dive

    2. Laza Medical raises up to $160M Series B led by GE HealthCare for AI robotic cath lab imaging

    On 4 November Laza Medical, a Shifamed portfolio company based in Los Gatos, California, announced a Series B structured financing of up to $160 million led by GE HealthCare, with returning investors Unorthodox Ventures, PA MedTech and AMED also participating. The money will advance its AI powered robotic imaging system for cardiac interventions. The Laza Medical System is under development and is not approved for commercial sale in any geography. It matters because a large imaging group is putting serious capital behind an AI robotics startup, and it was one of the week’s biggest device financings.

    Source: PR Newswire (Laza Medical)

    3. Rockwell Medical agrees to buy Vantive’s hemodialysis business for a $125M base price

    On 3 November Rockwell Medical (Nasdaq: RMTI) announced an Equity and Asset Purchase Agreement with Vantive Limited to acquire Vantive’s hemodialysis concentrates, HD machines including the AK-98, water treatment systems, and related consumables and technical services, together with Vantive’s one million square foot manufacturing campus in Medolla, Italy. The base purchase price is $125 million, financed through two $50 million term loans from Vantive and a $25 million convertible note, and Vantive may receive up to $45 million more in contingent consideration based on revenue and EBITDA milestones. The combined business is projected to generate annual revenue between $400 million and $450 million, and the deal is expected to close in mid-2027, subject to regulatory approvals and other closing conditions. Vantive’s dialyzer portfolio, including the Theranova dialyzer, is not included. It matters because a focused US dialysis supplier is using an acquisition, largely financed by the seller, to become a much larger global hemodialysis manufacturer.

    Source: Rockwell Medical and PR Newswire (Vantive)

    4. Zylox-Tonbridge and GL Capital invest about HK$1.482 billion in LifeTech Scientific

    On 6 November Zylox-Tonbridge Medical Technology (HKEX: 2190) and GL Capital announced they will jointly invest approximately HK$1.482 billion in LifeTech Scientific (HKEX: 1302) through GL Lighthouse Two Investment Limited, which will subscribe for newly issued shares representing about 16.7% of LifeTech’s enlarged share capital and become its largest single shareholder. Zylox-Tonbridge will hold a 60% stake in Lighthouse Two through an investment of about HK$889 million. In a related transaction, GL Capital will subscribe for 39.8 million newly issued Zylox-Tonbridge shares at HK$22 per share, about 10.8% of the enlarged share capital, at a 13.5% premium to the closing price on the announcement date. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech, with the aim of building an integrated vascular and structural heart intervention platform in China. It matters because two listed Chinese device groups are using a large strategic stake, and a possible later merger, to put peripheral, neurovascular, aortic and structural heart products under one roof.

    Source: PR Newswire (Zylox-Tonbridge)

    5. Nanochap closes an RMB 500M Series C+ for its retinal vision implant

    On 3 November Hangzhou based Nanochap Electronics said it had closed an RMB 500 million Series C+ round led by Gaorong Ventures, with PICC Equity, Monolith, C&D Emerging Investment, Orient Jiafu, Danhe Capital and Hangzhou Industrial Investment Group joining, and existing shareholders including Legend Capital increasing their stakes. It is the company’s second round of 2026 after an RMB 300 million strategic round in May, bringing total funding to RMB 1 billion. Its E-BCI system pairs a 3 by 3 millimetre retinal implant with camera glasses, a registration trial is under way at three hospitals with three patients implanted so far, and the company aims for 30 implants in 2026 and to seek commercial approval in 2027. It matters because vision restoration is becoming its own funded category inside China’s fast growing BCI sector.

    Source: Inside BCI

    6. Active Technology raises an RMB 464M Angel+ round for invasive BCI

    On 4 November Shanghai Active Technology (主动科技), a Lingang Laboratory spinout founded in February 2026, announced an RMB 464 million (about $69.3 million) Angel+ round co led by Gaorong Ventures, SDIC Pilot Fund and Shanghai Science and Technology Venture Capital, with eight new investors and three existing shareholders joining. Together with its RMB 330 million angel round announced on 3 August, it has raised about RMB 800 million (about $119 million) in under three months, which Chinese media describe as a record for the angel stage in China’s BCI field. Its lead product, Tianshu, is a motor BCI aimed at movement and speech loss after stroke, spinal cord injury and ALS, and no human implant has yet been reported. It matters because Chinese investors are now paying later stage prices for very early implantable neurotech.

    Source: VCBeat and GS MedTech Funding Tracker

    7. Shanghai Yingjiexin closes an RMB 200M Series B for injection pens and autoinjectors

    On 5 November Shanghai Yingjiexin Medical Technology (Enjosim Medical) announced an RMB 200 million Series B (about $27.5 million) led by CICC Capital, with Zhuhai Technology Industry Group, CoStone Capital, Qiming Venture Partners and others joining, and existing backer Photon Venture Capital reinvesting. The company makes disposable prefilled pens, reusable injection pens and autoinjectors for biologics such as GLP-1 drugs, insulin and growth hormone, and says the money funds overseas registration and global production capacity. It matters because the GLP-1 boom is pulling Chinese drug delivery hardware makers into global supply chains, where the pharma partner, not the device maker, usually carries the filing.

    Source: MedDevice Startups and GS MedTech Funding Tracker

    8. OSSTEC closes $8M to take its cementless partial knee toward first US cases

    On 3 November London based OSSTEC, a 2021 spinout from Imperial College London, announced it had closed $8 million led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures. The capital will take ASCENT, its cementless fixed bearing partial knee system, and its CLARITY instrumentation through FDA clearance to first in human procedures in the United States, planned for the first half of 2027, and will also advance a 3D printed fixation platform. ASCENT and CLARITY are not cleared by the FDA and are not available for sale in the United States. It matters because European orthopedic innovation is still finding the capital to cross the Atlantic, one clearance and one first case at a time.

    Source: Business Wire (OSSTEC)

    9. NIH SBIR awards back respiratory monitoring and Parkinson’s neuromodulation

    On 5 November Baltimore based Linshom Medical announced a $3.5 million SBIR Phase 2B grant from the National Institutes of Health, National Heart, Lung and Blood Institute, to add wireless portable continuous respiratory monitoring and to run a multicenter clinical trial on the medical and economic benefits of earlier detection of respiratory decline. On 9 November Cambridge, Massachusetts based Highland Instruments announced a Phase IIB SBIR award from the National Institute of Neurological Disorders and Stroke for ESStim, its noninvasive neuromodulation platform for postural instability in Parkinson’s disease, with about $1.5 million in current year funding and about $1.4 million in recommended future support, for up to about $2.9 million in total, subject to availability of funds and satisfactory progress. ESStim has not been approved by the FDA for a specific clinical indication and is not in commercial distribution. It matters because non dilutive US grant money is still doing real work for smaller device teams, especially where the clinical path is long and a large commercial raise is not yet obvious.

    Source: Linshom Medical (EIN Presswire) and Highland Instruments

    Gary’s take

    What the money is telling us this week is that the biggest cheques are going to hard, capital heavy devices: a late stage heart pump, AI robotic imaging in the cath lab, and implantable brain interfaces in China, some of them still at a very early clinical stage. I also notice how deals are being structured, not only how large they are. Boston Scientific is sharing the cost of Vitalyst with Blackstone rather than carrying the whole programme on its own balance sheet, and Rockwell is buying a global dialysis business largely with seller financing. That tells me boards are looking for ways to move big assets without stretching the equity story too far. In China, Zylox-Tonbridge and LifeTech are using a large strategic stake, and talking about a possible merger, to build a broader vascular platform, which is a reminder that scale and a complete portfolio still matter there. The quieter NIH grants to Linshom and Highland are a useful counterpoint, because not every important programme needs a nine figure round, and non dilutive money remains a serious tool for smaller teams. My advice is to look as closely at the structure of a deal as at the headline number, because that is often where the real signal sits.

    Which of these funding stories matters most for your company, and is there a type of deal you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of about 3 to 10 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. The Boston Scientific and Blackstone agreement was announced on 2 November, just as this window opened.

    Download the full roundup as a PDF

  • What’s new this week in Asian MedTech, 2 to 8 November 2026

    What’s new this week in Asian MedTech, 2 to 8 November 2026

    2 to 8 November 2026

    Another busy Asian week, led again by Chinese capital. Nanochap and Active Technology raised large rounds for implantable brain computer interfaces, Shanghai Yingjiexin closed a Series B for injection pens, and Rhino Health raised a B+ round to commercialise China’s first homegrown phaco vitrectomy system. Taiwan’s Ever Fortune.AI won a US FDA clearance for AI stroke triage, Japan saw a new NGS companion diagnostic approval and a Nihon Kohden sleep software clearance, and Korea added a portable wound therapy device and a government backed surgical training project.

    1. Nanochap closes an RMB 500M Series C+ for its retinal vision implant

    On 3 November Hangzhou based Nanochap Electronics said it had closed an RMB 500 million Series C+ round led by Gaorong Ventures, with PICC Equity, Monolith, C&D Emerging Investment, Orient Jiafu, Danhe Capital and Hangzhou Industrial Investment Group joining, and existing shareholders including Legend Capital increasing their stakes. It is the company’s second round of 2026 after an RMB 300 million strategic round in May, bringing total funding to RMB 1 billion. Its E-BCI system pairs a 3 by 3 millimetre retinal implant with camera glasses, a registration trial is under way at three hospitals with three patients implanted so far, and the company aims for 30 implants in 2026 and to seek commercial approval in 2027. It matters because vision restoration is becoming its own funded category inside China’s fast growing BCI sector.

    Source: Inside BCI

    2. Active Technology raises an RMB 464M Angel+ round for invasive BCI

    On 4 November Shanghai Active Technology (主动科技), a Lingang Laboratory spinout founded only in February 2026, announced an RMB 464 million Angel+ round co led by Gaorong Ventures, SDIC Pilot Fund and Shanghai Science and Technology Venture Capital, with eight new investors and three existing shareholders joining. Together with its RMB 330 million angel round announced on 3 August, it has raised about RMB 800 million in under three months, which Chinese media describe as a record for the angel stage in China’s BCI field. Its lead product, Tianshu, is a motor BCI aimed at movement and speech loss after stroke, spinal cord injury and ALS, and no human implant has yet been reported. It matters because Chinese investors are now paying later stage prices for very early implantable neurotech.

    Source: VCBeat and NeuroTechGuide

    3. Shanghai Yingjiexin closes an RMB 200M Series B for injection pens and autoinjectors

    On 5 November Shanghai Yingjiexin Medical Technology (Enjosim Medical) announced an RMB 200 million Series B (about $27.5 million) led by CICC Capital, with Zhuhai Technology Industry Group, CoStone Capital, Qiming Venture Partners and others joining, and existing backer Photon Venture Capital reinvesting. The company makes disposable prefilled pens, reusable injection pens and autoinjectors for biologics such as GLP-1 drugs, insulin and growth hormone, and says the money funds overseas registration and global production capacity. It matters because the GLP-1 boom is pulling Chinese drug delivery hardware makers into global supply chains, where the pharma partner, not the device maker, usually carries the filing.

    Source: MedDevice Startups and Guided Solutions funding tracker

    4. Rhino Health raises a B+ round to scale China’s first homegrown phaco vitrectomy system

    On 5 November VCBeat reported that Rhino Health, a developer of high end ophthalmic surgical equipment, closed a B+ round of nearly RMB 100 million led by In Capital, with Zhuhai Technology Industry Group participating. Its Genesis I and II combined phaco vitrectomy system was approved by NMPA on 15 December 2025 as the first product of its kind in China. Since commercial launch in June the company has signed contracts for more than 30 units and completed more than 10 installations, and founder Zhang Chi expects full year signings to approach 60 units. CE and FDA registration testing is complete. It matters because a domestic player is now competing directly with Alcon and Bausch + Lomb in one of ophthalmology’s most expensive equipment categories.

    Source: VCBeat

    5. Taiwan’s Ever Fortune.AI wins US FDA 510(k) clearance for AI large vessel occlusion detection

    On 2 November Taiwan’s Ever Fortune.AI (長佳智能) announced US FDA 510(k) clearance for its large vessel occlusion detection system, its 16th FDA clearance. The deep learning software analyses head CT angiography, flags suspected large vessel occlusions in the internal carotid artery and the M1 and M2 segments of the middle cerebral artery, and alerts the hospital PACS and RIS, with reported sensitivity of 96% and specificity of 94%. Combined with its existing brain haemorrhage and midline shift products, it now covers both haemorrhagic and ischaemic stroke, and the company holds 58 device licences worldwide, including 24 from Taiwan’s TFDA. It matters because a Taiwanese AI company is competing in US stroke triage, one of the most crowded imaging AI categories.

    Source: Commercial Times

    6. Thermo Fisher wins Japan’s first approval for the Oncomine Dx Express Test multi CDx system

    On 2 November Thermo Fisher Scientific Japan announced that on 30 October Japan’s MHLW approved the Oncomine Dx Express Test Multi CDx System, its first approval in Japan. The NGS based companion diagnostic identifies AKT1, PIK3CA or PTEN alterations in breast cancer for capivasertib, and NTRK1, NTRK2 and NTRK3 fusions in solid tumours for larotrectinib. Running on the Ion Torrent Genexus system, it automates the workflow from sample preparation to report and can deliver results in as little as 24 hours. Reimbursement procedures are still to follow. It matters because Japan is moving companion diagnostics toward faster, automated in hospital sequencing.

    Source: Thermo Fisher Scientific Japan

    7. Nihon Kohden’s Neurotronics wins FDA clearance for AI sleep analysis software

    On 3 November Neurotronics, a Nihon Kohden company, announced US FDA 510(k) clearance for its Sleep Analysis Module (SAM), with Nihon Kohden publishing the news on 6 November. The software only device uses the PPG signal already collected by a pulse oximeter to estimate total sleep time, so home sleep studies can measure apnea severity against estimated sleep time rather than total recording time, without extra sensors. It will first be integrated into Polysmith software for the NomadAir home sleep apnea test, and it is Neurotronics’ first FDA cleared AI/ML sleep algorithm. It matters because a Japanese monitoring group is adding value to home sleep testing through software rather than new hardware.

    Source: Nihon Kohden

    8. CGBio brings the portable single use Curasis Me wound therapy device to Korea

    On 3 November CGBio, the regenerative medicine affiliate of the Daewoong group, said its self developed Curasis Me portable single use negative pressure wound therapy system had received Korean MFDS approval on 22 September. It is smaller than the existing Curasis but applies the same negative pressure of minus 125 mmHg, and is approved for closed surgical incisions as well as chronic, acute and traumatic wounds, partial thickness burns, diabetic ulcers and pressure sores, so patients can continue treatment at home after discharge. Its predecessor Curasis2 is already sold in Thailand, the Philippines, Vietnam and China. It matters because wound care is following the wider shift of treatment from hospital to home.

    Source: ChosunBiz

    9. Medinnoa wins KRW 1 billion TIPS backing for AI and XR "digital clone" procedure training

    On 6 November Korean medical AI and XR company Medinnoa said it had been selected for the 2026 TIPS general track (third round), receiving KRW 1 billion in R&D support for an AI based digital cloning simulation solution for image guided interventional procedures. Its Medinnopia platform builds patient specific 3D models from CT and other images so physicians can rehearse procedures in XR, with realistic responses such as bleeding when a vessel is punctured. The funds go to digital clone accuracy, clinician usability testing and spatial tracking of patients and tools. It matters because Korea’s TIPS programme keeps seeding the training and planning tools that sit around devices, not only the devices themselves.

    Source: Money Today

    Gary’s take

    Two weeks in a row, the loudest story in Asia is Chinese money flowing into implantable brain computer interfaces. Nanochap and Active Technology together raised close to RMB 1 billion this week, only days after NeuroXess, and one of them has not yet implanted a single patient. I find that exciting and a little worrying at the same time, because capital can move faster than clinical evidence. The quieter stories teach me just as much: Rhino Health is proving a domestic device can win hospital contracts against the global giants, Ever Fortune.AI shows a Taiwanese team can earn its sixteenth FDA clearance in stroke, and Nihon Kohden and CGBio are both moving care toward the home. Having spent my career in sleep and stroke, it is good to see both fields so well represented. My advice to anyone planning Asia is the same as last week: the region rewards patience, local partners and real evidence, one country at a time.

    Which of these Asian stories matters most for your company, and is there a country or category you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of 2 to 8 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media.

    Download the full roundup as a PDF

  • What’s new this week in Indian MedTech, 2 to 8 November 2026

    What’s new this week in Indian MedTech, 2 to 8 November 2026

    2 to 8 November 2026

    A busy Indian week across funding, local manufacturing, critical care launches, import logistics, industry-academia ties and device safety: Clinics On Cloud raised Rs 120 crore in its first institutional round for CDSCO licensed Health ATMs, Omron Healthcare began full-scale production of blood pressure monitors at its first India factory near Chennai, Allied Medical launched the made-in-India ALTUS ventilator series, the health ministry proposed ten new import gateways for drugs and medical devices, the Association of Tamil Nadu Medical Device Industry signed an MoU with Anna University, Sahajanand Medical Technologies approved a further investment of up to USD 7,80,000 in US startup SNP Medical Corp, BTC Health added India to its exclusive Exstent partnership for the ExoVasc PEARS aortic implant, subject to CDSCO import approval, and the Indian Pharmacopoeia Commission disclosed 9,373 serious medical device adverse events since 2020.

    1. Clinics On Cloud raises Rs 120 crore Series A for CDSCO licensed Health ATMs

    Covered on 2 to 4 November, Pune based Clinics On Cloud raised Rs 120 crore (about $12.5 million) in a Series A from Dubai based investors through Model42, a healthcare investment platform powered by Enlightened Minds Investments, at a reported Rs 600 crore valuation. It is the company’s first institutional round after eight bootstrapped years. Founded in 2018 by Abhay Agarwal and Manashrri Agarwal, the firm describes itself as a CDSCO licensed maker of Health ATM screening kiosks, along with Health Lounges, Box Clinics and Mobile Medical Units. It claims more than 3,500 deployments and over 12 million screenings across India and eight other countries, and manufactures at Chakan MIDC near Pune. Proceeds are earmarked for AI and research and development, manufacturing scale, international regulatory work and a UAE led push into Africa, the United States and Southeast Asia. It matters because a CDSCO licensed Indian screening device platform is now using Gulf capital to export connected microclinics, not only sell inside India.

    Source: Indian Startup News and Medical Buyer

    2. Omron Healthcare starts full-scale production at its first India factory near Chennai

    On 30 October, with further coverage on 2 November, Omron Healthcare announced the start of full-scale blood pressure monitor production at the OMRON Group’s first factory in India, at Origins by Mahindra in Puduvoyal, Gummidipoondi, near Chennai. The Hindu reported that the plant was formally inaugurated on 30 October. It is operated by OMRON HEALTHCARE MANUFACTURING INDIA Pvt. Ltd., incorporated in July 2022, and the official announcement lists a site of about 24,000 square metres, five production lines, about 120 employees and capitalisation of INR 1.91 billion. The lines make the HEM-7090, HEM-7181 and HEM-7183T series for the Indian market, using production and quality methods developed at Omron’s Matsusaka factory in Japan and its Vietnam facilities. The Hindu said the plant is designed to make about 300,000 monitors a year, with a plan to raise capacity tenfold to 30 lakh units a year (about 3 million) within two years; the company and later coverage dated that tenfold target to 2028. Omron estimates that about 300 million people in India live with hypertension, while fewer than 5% of households regularly use a home blood pressure monitor. President and CEO Ayumu Okada said the Chennai start is a step toward a stable supply of medical-grade monitors in India. The company also plans to develop Chennai as a supply base for international markets, including exports to Europe, and to add nebuliser production later, though no timeline was given for the nebulisers. It matters because a global home monitor leader is now running full-scale production in Tamil Nadu, which is exactly the kind of high volume manufacturing India says it wants under Make in India.

    Source: Omron Healthcare press release and The Hindu

    3. Allied Medical launches the ALTUS made-in-India ICU ventilator series

    On 2 November Allied Medical Limited launched ALTUS, a new series of ventilators designed and built in India, at an event with the company’s channel partners and staff. Founded in 1982, Allied Medical positioned the series as part of its effort to make advanced critical care technology accessible through indigenous design and manufacturing. The company describes ALTUS as intelligent, adaptive and versatile, with features developed around what clinicians need in intensive care units and emergency settings where patients depend on assisted breathing. Trade coverage named Chairman Dr. Vinod Kohli and Joint Managing Directors Akhil Kohli and Aditya Kohli as the leadership behind the launch. It matters because ventilators remain a strategic, often import heavy category, and a long standing Indian manufacturer putting a new series into ICUs is another step toward serving that demand from home.

    Source: Medgate Today and Exceptional Technology

    4. Health ministry proposes ten new import gateways for drugs and medical devices

    On 4 November ETHealthWorld and Medical Buyer reported that the Union Ministry of Health and Family Welfare has proposed a draft amendment to Rule 43A of the Drugs Rules, 1945, adding inland container depots, a special economic zone and an international airport to the list of authorised entry points for importing drugs, medical devices and cosmetics. The ten proposed additions are ICD Sonipat, ICD Piyala and ICD Harsaru in Haryana; ICD Dadri and Noida International Airport in Uttar Pradesh; ICD Gandhidham/Mundra in Gujarat; ICD Sanath Nagar and ICD Thimmapur in Hyderabad, Telangana; and ICD Whitefield and SEZ Bommasandra in Karnataka. They would join existing authorised points, including the ICDs at Dhannad and Tihi in Indore. The ministry said the change should let importers clear consignments closer to factories, warehouses and distribution centres, cutting inland transport, logistics costs and delays. The Medical Technology Association of India welcomed the proposal, while cautioning that the gains depend on adequate regulatory infrastructure at the new sites. The draft is open for objections and suggestions. It matters because so much of India’s device industry still depends on imported components and finished equipment, and clearance closer to factories and hospitals is a practical cost and time issue, not a slogan.

    Source: ETHealthWorld and Medical Buyer

    5. ATMED and Anna University sign MoU to deepen Tamil Nadu device industry-academia ties

    The Hindu reported on 8 November that the Association of Tamil Nadu Medical Device Industry (ATMED) and Anna University have signed a memorandum of understanding to strengthen industry-academia collaboration in the state’s medical device sector. According to a press release cited by The Hindu, the MoU was exchanged on 3 November at Anna University between V. Kumaresan, registrar of Anna University, and Samuel William George, president of ATMED. The partnership is intended to bridge academic training and industry needs through student internships, industry exposure, employment opportunities, technical training, research, product development and technology commercialisation, as well as joint workshops, seminars, faculty-industry interactions, student innovations and access to Anna University’s technical infrastructure. ATMED said it will use its member-company network to support mentorship, industrial exposure and the development of skilled professionals and indigenous medical technologies. Office bearers of ATMED and professors from Anna University’s Biomedical Engineering Department were present. It matters because device parks and incentive schemes only work if the state also has engineers, technicians and industry-ready graduates, and Tamil Nadu is trying to join those dots directly.

    Source: The Hindu

    6. SMT approves further investment of up to USD 7,80,000 in US startup SNP Medical Corp

    On 5 November the Board of Directors of Sahajanand Medical Technologies Limited approved an investment by its wholly owned subsidiary, Sahajanand Medical Technologies Ireland Limited (SMT Ireland), in SNP Medical Corp., a US medical device startup registered in Delaware on 31 May 2022. An NSE filing signed by Managing Director and CEO Bhargav Dhirajlal Kotadia puts the cash acquisition cost at up to USD 7,80,000, with the price per share to be set from a valuation of SNP. SMT Ireland held a 14.15% stake as on 30 September 2026, and the new investment would raise that holding to up to 17.19%. Completion is tentatively targeted by 31 March 2027. SMT disclosed the deal as a related party transaction at arm’s length, because Priyanka Cohen, a Promoter and Non-Executive Director of SMT, is a Director in SNP. The filing gives SNP’s turnover as USD 3,00,000 in 2025, USD 2,34,960 in 2024 and USD 5,64,930 in 2023, and describes the object as diversification of SMT’s product portfolio within its existing main line of business. It does not name a specific SNP product. It matters because one of India’s newly listed cardiovascular device makers is using a modest further cheque to deepen a US foothold, a reminder that going public is also about building a broader product pipeline.

    Source: NSE filing (Sahajanand Medical Technologies)

    7. BTC Health adds India to its exclusive Exstent partnership for ExoVasc PEARS

    On 6 November ASX-listed BTC Health Limited announced that its wholly owned investee company, BTC Cardio Pty Ltd, has signed a new exclusive distribution agreement with UK-based Exstent Limited for ExoVasc PEARS (Personalised External Aortic Root Support), covering Australia and India. PEARS is a custom-made mesh support, manufactured from each patient’s CT scan and fitted around the aorta to prevent further dilatation. It is used in patients with an enlarged aortic root, including those with Marfan syndrome, and to support the pulmonary autograft in the Ross procedure (Ross-PEARS), preserving the patient’s own aortic root and valve. The new agreement runs for an initial five years, renews automatically for further two-year periods unless either party gives notice, and replaces the April 2024 Australia-only agreement. No upfront or milestone payment is payable to Exstent. In Australia, PEARS revenue grew 20% to $1.10 million in FY26. Sales in India will begin only once CDSCO grants import approval; BTC Cardio said regulatory consultants are engaged, discussions with Indian aortic surgeons have begun, and Exstent will support the submissions. India’s inclusion is subject to obtaining Indian approvals within an agreed timeframe. Executive Chair Dr Richard Treagus said the company had been preparing for India for much of the year and would start with leading surgical centres. Exstent, based in Tewkesbury, Gloucestershire, said the first ExoVasc PEARS was implanted at the Royal Brompton Hospital in London in 2004, and that more than 1,500 patients have since been treated at more than 40 surgical centres worldwide. It matters because a specialised aortic implant is now on a formal path toward India, and the real gate is still CDSCO import approval, not the distribution contract itself.

    Source: BTC Health ASX announcement

    8. IPC discloses 9,373 serious medical device adverse events in India since 2020

    On 6 November The Indian Express reported, with Outlook India repeating the figures the same day, that the Indian Pharmacopoeia Commission has for the first time disclosed the number of Serious Adverse Events caused by medical devices in India since 2020: 9,373, rising from 808 in 2020 to 2,176 in 2025, a nearly three-fold increase over six years. The newspaper said it accessed the data on 27 October after a 10 September part-compliance order by a Central Information Commission bench led by Information Commissioner Jaya Varma Sinha. SAEs are events that may result in life-threatening conditions or prolonged hospitalisation. The IPC has published broader Medical Device Adverse Event totals from 775 monitoring centres under the Materiovigilance Programme of India, launched in 2015, while keeping the serious-event numbers restricted. Manufacturer names and device categories were not released. The IPC argued that disclosure would breach commercial confidence under Section 8(1)(d) of the RTI Act, and the Commission held that brand details could not be shared because it was not conclusively established whether events arose from a procedural lapse or from the device itself. In financial year 2024-2025 the IPC logged 14,584 MDAEs and forwarded only 22 cases to CDSCO; the comparable figures were 10,269 MDAEs and 16 cases in 2023-2024, and 3,868 MDAEs and 12 cases in 2022-2023. It matters because India has now put a public number on serious device-related harm, while still withholding the names of devices and manufacturers, which limits how much hospitals, patients and domestic makers can learn from the data.

    Source: The Indian Express and Outlook India

    Gary’s take

    What stands out for me this week is that Indian medtech is being built in factories and in the unglamorous systems around them, not only in pitch decks. Omron has started full-scale production of blood pressure monitors at its first India plant near Chennai, and Allied Medical has launched a new made-in-India ICU ventilator series. Clinics On Cloud’s first institutional round, Rs 120 crore after eight bootstrapped years, shows that investors will still back a CDSCO licensed screening platform that is already out in the field. At the same time, the health ministry wants more inland gateways so devices and components clear closer to factories and hospitals, Tamil Nadu’s device association is tying itself closer to Anna University, SMT is putting a further sum of up to USD 7,80,000 into a US device startup, and an Australian distributor is preparing ExoVasc PEARS for India once CDSCO grants import approval. Overlay the Indian Pharmacopoeia Commission’s first public count of serious device adverse events, 9,373 since 2020, and the picture is more complete. Capacity is rising. So is the need for faster logistics, honest safety data and regulators who can keep up. If you sell into India, or build here, none of that is optional.

    Which of these Indian stories matters most for your company, and is there a state, therapy area or company type you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source. Omron’s factory opening and start of full-scale production were announced on 30 October, with further coverage on 2 November, and that earlier date is stated in the text.

    Download the full roundup as a PDF

  • What’s new this week in Israeli MedTech, 31 October to 6 November 2026

    What’s new this week in Israeli MedTech, 31 October to 6 November 2026

    What’s new this week in Israeli MedTech

    31 October to 6 November 2026

    A strong Israeli week across funding, exits, hospital AI and clearances abroad: StimCardio raised a large Series A for a wearable AF therapy, TailorMed took a reported quarter billion dollar majority deal, ZOLL Itamar and MeMed both advanced US clearances, Ichilov partnered with Wonderful on AI agents, Sofwave posted profitable growth with China NMPA approval, and Schneider Children’s opened Israel’s first dedicated pediatric health VC.

    1. StimCardio closes a $30M Series A for a wearable atrial fibrillation therapy Announced on 29 October and widely covered in Israeli and US trade press early this week, Israeli medical device company StimCardio closed an oversubscribed $30 million Series A led by Metis Medtech, with Catalyst Health Ventures, corporate strategics and other new and existing investors. The raise funds the NeuroPulse 2 pivotal study of Rhyvive, an investigational wrist worn median nerve stimulation wearable meant to reduce AF recurrence after catheter ablation, and preparation for an FDA De Novo submission. It matters because a home adjunct to ablation is drawing serious cardiac device capital, and recurrence after ablation remains a stubborn clinical gap. Source: StimCardio and MobiHealthNews

    2. TailorMed takes a GrowthCurve Capital majority investment in a reported ~$250M deal On 2 November TailorMed announced a majority investment from New York private equity firm GrowthCurve Capital. Calcalist reported the deal at about $250 million, with most existing shareholders expected to sell; the companies did not disclose the figure. The Israeli founded digital health company connects patients to medication access, affordability and adherence support across more than 950 hospitals, 4,700 clinics and 3,100 pharmacies, and says it has helped secure more than $7.4 billion in patient financial assistance since 2020. It matters because a US focused Israeli digital health platform has reached a real exit scale while keeping its Tel Aviv development centre. Source: TailorMed and Ctech

    3. ZOLL Itamar gets FDA 510(k) for PolySense, taking WatchPAT 400 to home PSG On 2 November ZOLL announced FDA 510(k) clearance for PolySense accessories that expand the WatchPAT 400 from a home sleep apnea test to home polysomnography. Self applied head, cardiac and leg patches record EEG, EOG, EMG, ECG and leg movement, and with the full kit the platform can measure up to 11 channels and 9 parameter categories referenced by the AMA CPT Assistant from 1 January 2027. US availability is planned for early January 2027. It matters because one of Israel’s signature sleep tech platforms, now under ZOLL Itamar, is moving advanced sleep studies out of the lab and into the home. Source: ZOLL

    4. Beckman Coulter wins FDA clearance for Access MeMed BV, the Israeli host response assay On 3 November Beckman Coulter Diagnostics announced US FDA clearance of Access MeMed BV, developed with Haifa based MeMed. The host response blood test measures TRAIL, IP-10 and CRP to help distinguish bacterial from viral infection in adults and children as young as 90 days, with results in as little as 15 minutes on the DxI 9000 analyzer and also available on Access 2. The assay already held a CE mark from April 2026. It matters because an Israeli host response technology is now sitting on major US lab instruments, which is how antimicrobial stewardship tools actually scale. Source: Beckman Coulter

    5. Ichilov partners with Wonderful to build AI agents inside the hospital On 3 November Tel Aviv Sourasky Medical Center (Ichilov) announced a strategic partnership with Israeli AI company Wonderful to develop, test and deploy AI agents across clinical, operational and service workflows on Wonderful’s operating system, including work toward an agentic medical record. Wonderful recently raised $550 million at a $5 billion valuation. Hospital CEO Prof. Eli Sprecher framed the goal as freeing medical teams’ time for patients. It matters because a major Israeli hospital is not only buying AI tools, it is co developing them in a live clinical setting as a model for other systems. Source: Ichilov and Ynet

    6. Sofwave posts $28.5M Q3 revenue (+35%) and China NMPA approval On 3 November TASE listed Sofwave Medical reported third quarter revenue of $28.5 million, up 35% year over year, with usage fee revenue of $13.3 million (+60%) and IFRS net income of $4.1 million. Nine month revenue reached $82.9 million (+41%). In the same quarter China’s NMPA approved the Sofwave System for mid to lower facial wrinkles in adults 22 and older, supported by a 200 subject study in China, with an initial order for 70 systems. It matters because an Israeli founded aesthetics device company is compounding recurring usage revenue while opening one of the largest aesthetic markets. Source: GlobeNewswire (Sofwave)

    7. Schneider Children’s opens Israel’s first pediatric focused VC with a $20M first close On 4 November Calcalist reported that Schneider Children’s Medical Center, with Clalit, is launching Schneider Children’s VC (SCVC), Israel’s first fund dedicated to pediatric healthcare innovation. The fund has raised about $20 million in an initial closing toward a $50 million target, has already invested in three companies at $500,000 to $3 million each, and is anchored by Schneider, Clalit, the Dor Group and managing partner Ronen Gadot. It matters because pediatrics still gets a thin slice of life science capital, and tying a hospital, a payer and a fund together can shorten the path from concept to clinic. Source: Ctech

    Gary’s take

    What stands out for me this week is how Israeli medtech is winning on more than one front at once: fresh device capital for StimCardio, a real digital health exit for TailorMed, and US clearances that put Israeli science on global platforms, as with MeMed on Beckman analyzers and WatchPAT moving into home PSG. On a personal note, I had the privilege of working at Itamar in its early days and opened its first US office with the very first WatchPAT, back when there wasn’t even a CPT code and all the societies were against home sleep testing. So seeing WatchPAT move into home PSG today really warms my heart. The Ichilov and Wonderful partnership is also worth watching, because hospitals that co develop AI in the ward, rather than only buying it from outside, will set the bar for everyone else. And Schneider Children’s new fund is a reminder that if we want better tools for kids, we have to finance them as a category of their own, not as a smaller version of adult care.

    Which of these Israeli stories matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com
    LinkedIn: linkedin.com/company/100981535
    YouTube: youtube.com/@synergenmedtech


    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source. Trial edition for the new Saturday Israeli MedTech roundup.

    Download the full roundup as a PDF

  • They Saw the Future. They Waited.

    They Saw the Future. They Waited.

    Kodak helped invent the digital camera. Blockbuster was offered a partnership with Netflix. Nokia held almost 40% of the world’s phone market. All three saw the future coming, and all three chose to protect what was already working. That one mistake cost them everything.

    I see the same pattern in MedTech all the time. A company has a great product, a loyal group of physicians and a sales model that once worked well. Then reimbursement changes, a competitor moves to home care, or AI changes what buyers expect, and the team waits a little too long because the old way still pays the bills.

    I lived this from the other side. When I opened Itamar Medical’s first US office with the first WatchPAT, there was no CPT code and the sleep societies opposed home sleep testing. The market looked closed. We bet on where care was going, not where it was, and that bet paid off.

    That is what we do at Synergen MedTech Consultants. We help MedTech companies look honestly at where their market is heading, then build the strategy, the business development plan and the funding to get there first. Sometimes that means rethinking the go-to-market model. Sometimes it means a grant application that pays for the next product. And sometimes it simply means asking the hard question before the market asks it for you.

    The future does not wait. If you would like a fresh pair of eyes on where your company is heading, I’d be glad to talk.

    #MedTech #Innovation #Strategy #BusinessDevelopment #HealthTech

    If you’d like to follow along, you can find us here:

    Website synergenmedtech.com
    LinkedIn linkedin.com/company/100981535
    YouTube youtube.com/@synergenmedtech

  • What’s new this week in MedTech, 31 October to 6 November 2026

    What’s new this week in MedTech, 31 October to 6 November 2026

    What’s new this week in MedTech

    31 October to 6 November 2026

    A busy week for clearances and capital: FDA opened a new non invasive vein care category, Boston Scientific locked in a large heart pump co funding deal, AI imaging raised a major Series B, and Siemens Healthineers set out a path to rename and carve out diagnostics, while real world hypertension data and a long running recall settlement both moved the needle for market access.

    1. Theraclion wins FDA De Novo for Sonovein, a non invasive HIFU treatment for varicose veins On 4 November Theraclion announced FDA De Novo marketing authorization for Sonovein for coagulation of blood vessels in patients with superficial venous reflux in Great Saphenous Vein segments, describing it as the first non invasive high intensity focused ultrasound platform authorized in the United States for this use. The filing was supported by the VEINRESET pivotal study in 70 patients, which reported 96.8% GSV occlusion at 12 months as the primary endpoint, and a Category III CPT code for non invasive HIFU vein procedures has been active since 1 October 2026. It matters because it opens the large US varicose vein market to an incision free modality and creates a new device classification through the De Novo route. Source: Business Wire (Theraclion)

    2. Boston Scientific and Blackstone Life Sciences agree up to $455M to co fund the Vitalyst heart pump On 2 November Blackstone Life Sciences said it will provide up to $455 million to co fund development of Boston Scientific’s VITALYST Temporary Percutaneous Transvalvular Circulatory Support System for acute myocardial infarction cardiogenic shock, the first Blackstone Life Sciences co funding of a Boston Scientific product. Blackstone may receive regulatory and commercial milestones of up to about 2.5 times capital plus royalties, and Boston Scientific has pointed to commercial timing around 2030. It matters because a high mortality indication is getting one of the largest external co funding packages in medtech this year, which is a model more device companies will watch closely. Source: Blackstone and MedTech Dive

    3. Laza Medical raises up to $160M Series B led by GE HealthCare for AI robotic cath lab imaging Announced on 4 November, the Shifamed portfolio company closed a Series B structured financing of up to $160 million led by GE HealthCare, with Unorthodox Ventures, PA MedTech and AMED also participating, to advance its AI powered robotic imaging system for the cath lab. The system is not approved for commercial sale anywhere. It matters because it pairs a large imaging OEM with an AI robotics startup at scale, and it was one of the week’s biggest device financings. Source: PR Newswire (Laza Medical)

    4. FX Shoulder Solutions gets FDA 510(k) for the first stemless reverse shoulder system in the US On 5 November FX Shoulder Solutions announced FDA 510(k) clearance for Easytech Reversed, which it describes as the first and only FDA cleared stemless reverse shoulder arthroplasty system in the United States. Clearance follows an IDE started in 2018 across 7 sites and 90 patients, with follow up completed in 2023, and the design uses peripheral proximal humeral fixation without a conventional diaphyseal stem. It matters because it creates a new US option category in reverse shoulder replacement after a long clinical path. Source: PR Newswire (FX Shoulder Solutions)

    5. Medtronic Symplicity Spyral shows large real world blood pressure drops and gains a labeling update At TCT 2026 on 3 November, Medtronic reported six month results from the US primary cohort of SPYRAL AFFIRM, an FDA designed post approval study: office systolic blood pressure fell 18.2 mmHg, home 9.4 mmHg and 24 hour ambulatory 9.7 mmHg, with medication count unchanged at 3.6 and a composite safety rate of 2.1%. The same day FDA approved a US labeling update that adds clinical evidence for isolated systolic hypertension, chronic kidney disease up to stage 3b (eGFR of 30 or above) and type 2 diabetes, while the indication for use itself is unchanged. It matters because real world evidence and broader labeled evidence help hospitals decide who to treat, even when the formal indication stays the same. Source: Medtronic News

    6. Philips books EUR 288M for a DOJ agreement in principle over the Respironics recall On 3 November, with its Q3 results, Philips said Respironics reached an agreement in principle with the US Department of Justice to resolve criminal and civil investigations tied to the sleep and respiratory device recall, and recorded a provision of EUR 288 million (about $322 million as reported by trade press). Settlement is still subject to final documents, with payment expected in Q1 2027, and a separate US state attorneys general investigation remains open. It matters because one of the industry’s defining recalls is moving toward a criminal and civil resolution, which clears a large overhang even as state level work continues. Source: Philips SEC Form 6-K / Q3 materials and Fierce Biotech

    7. Evident Vascular wins FDA 510(k) for an AI powered peripheral IVUS platform On 4 November Evident Vascular announced FDA 510(k) clearance of the Evident Vascular Guidance System and Evident peripheral imaging catheters for ultrasound examination of intravascular pathology during peripheral vascular interventions. The platform emphasises high fidelity imaging, an AI workstation, flushless plug and play catheters and voice control, with NVIDIA accelerated processing. The company still notes that the system and catheters are not available for sale in the United States. It matters because peripheral IVUS is a workflow critical imaging niche, and an AI forward entrant raises the bar for competitors already in the cath lab. Source: Evident Vascular

    8. Siemens Healthineers to become Healthineers and carve out diagnostics as Olyrian On 5 November Siemens Healthineers said it will become Healthineers after the planned 2027 deconsolidation and spin off from Siemens, with shareholder votes expected in February 2027. Separately, its in vitro diagnostics business begins a carve out under the brand Olyrian Diagnostics, aiming to stand alone by mid 2028 while remaining part of Healthineers during the transition. It matters because one of the largest imaging and diagnostics groups is reshaping its name and structure, which will affect partners, competitors and talent across 117 countries and beyond. Source: Siemens press and Siemens Healthineers (Olyrian)

    Gary’s take

    What stands out for me this week is how many companies are using De Novo and 510(k) not just to get a product cleared, but to open an entirely new category, as Theraclion and FX Shoulder both did, and I would encourage any founder with a real unmet need that does not fit a predicate to look at De Novo early rather than forcing a 510(k) that does not fit. The Blackstone and Boston Scientific co funding model is also worth studying if you are raising for a capital heavy pivotal programme, because sharing late stage cost with a deep pocketed partner can protect your balance sheet without giving away the whole franchise. On the EU and large corporate side, name and structure changes like Healthineers do not change your CE plan overnight, so keep building on today’s rules and treat the spin outs as a signal of where the big groups are placing their bets.

    Which of these developments matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com
    LinkedIn: linkedin.com/company/100981535
    YouTube: youtube.com/@synergenmedtech


    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source.

    Download the full roundup as a PDF

  • International Business Development for MedTech Companies: Where Should You Start?

    International Business Development for MedTech Companies: Where Should You Start?

    I was born in South Africa and moved to Israel with my family when I was fifteen, and later I studied and worked in the United States, the United Kingdom, China and India. Living between countries early in life probably explains why international business development has always felt natural to me, but I have learned that it does not feel natural to most medical technology founders. For many of them, going international is something that happens after the product is finished. In my experience, the companies that succeed abroad start thinking about it much earlier, and they start in a more modest and more deliberate way than most people expect.

    So in this second article of the series I want to answer the question founders ask me most often once they accept that a good product is not enough: where do we actually start?

    Why international business development comes early for MedTech

    For companies from a small home market, international business is not a choice. Israel, Cyprus, Greece and many of the smaller EU countries are good examples. Many of them have sophisticated health systems, and Israel in particular has a remarkable number of medical technology companies. But for most of these companies, the domestic market can only ever be a reference site and a place to gather early experience. The real business has to be built abroad, which means international planning belongs in the first business plan rather than in the third.

    Even companies from large markets benefit from thinking internationally early. Regulatory work done with several countries in mind is far cheaper than regulatory work redone later. Clinical evidence designed with the expectations of more than one market in mind travels further. And the relationships that eventually lead to distribution agreements usually take years to mature, so the first conversations should happen long before the first order is needed.

    Start with an honest look at your readiness

    Before choosing any country, I ask a company to look honestly at itself. Is the device cleared somewhere, or close to clearance? Is there clinical evidence that a foreign physician would find convincing? Is there material, in English at least, that explains the product clearly to a distributor who has never heard of you? Is the product stable enough to be supported from thousands of kilometers away? And, perhaps the question founders least like to hear, is there someone in the company with the time and experience to travel, build relationships and follow up for several years?

    A company that answers no to most of these questions is not ready to sign distributors, but it is ready to start learning. That learning stage is valuable in itself. It is the time to attend the right trade fairs, talk to clinicians in two or three candidate markets, understand who pays for care in each of them, and meet potential partners without any pressure to sign.

    Resist the temptation to go everywhere at once

    Many years ago, for a company I represented at the time, I published a short LinkedIn article announcing that we were starting outreach to international distributors in the EU, the US and Asia. Looking at it today, I recognize the instinct very well, because almost every young company has it. You want to be everywhere, because every region looks promising and nobody wants to miss an opportunity.

    The advice I give founders now is to resist that instinct. A small company cannot support partners on three continents at once, and a distributor who feels unsupported quickly loses interest. It is far better to choose a few markets, enter them properly and use the results to earn the next ones. The way you choose those markets is important enough that I have given it its own article, which comes next in this series.

    Build the foundations once

    There are a few things worth building before the first market is chosen, because every later market will rely on them. The first is a regulatory file that is organized so that each new country can be added with a gap analysis rather than a completely new project. The second is a clear and simple commercial story: what the device does, which patients it helps, and why it matters to the person paying for it, told in a way that a distributor can repeat to a hospital. The third is a basic understanding of your own economics, so that you know what price a partner in another country would need in order to make a fair margin.

    None of this needs to be perfect. It needs to exist, because without it every international conversation starts from zero, and partners notice when a company has not done its homework.

    Use networks that already exist

    Founders often underestimate how much help is available at the start. Trade fairs, export institutes, embassies and industry associations exist precisely to connect companies with markets abroad. I serve as Director of Israel for FABA, the Federation of Asian Biotech Associations, whose flagship event, BioAsia, is held every year in Hyderabad, and through that role I see how much an introduction from a trusted network can shorten the first steps into a new region. A warm introduction from someone a distributor already trusts is worth far more than a hundred cold emails.

    The first step is a conversation

    When I describe the international work we do at Synergen, I say that we take a device that works into markets where it sells, one country at a time. The phrase “one country at a time” is deliberate. International business development is built from a long series of conversations, with clinicians, regulators, distributors and buyers, and each of them teaches you something about the next one.

    My PhD was in international law, and people sometimes ask what that has to do with business. More than you might think. Both are about understanding people, competing interests and decisions made under uncertainty, and both reward patience and preparation more than enthusiasm. That is the spirit in which I would encourage any founder to begin: with a few honest questions about readiness, a short list of candidate markets, and the willingness to go and listen before trying to sell.

    If you are trying to work out where your company’s international business should begin, I would be glad to talk it through. Write to me at gary@synergenmedtech.com and tell me about your commercialization or international business development challenges. In the next article, I look at how to choose the right international market for your device.

    All names of people and partners have been removed for privacy reasons.

    Website: synergenmedtech.com | LinkedIn: linkedin.com/company/100981535 | YouTube: youtube.com/@synergenmedtech